## Su Young Kim

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11290682/publications.pdf

Version: 2024-02-01

74 5,327 40 71
papers citations h-index g-index

74 74 74 5957 all docs docs citations times ranked citing authors

#	Article	IF	CITATIONS
1	PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas. Oncogene, 2005, 24, 1477-1480.	5.9	488
2	Increased expression of histone deacetylase 2 is found in human gastric cancer. Apmis, 2005, 113, 264-268.	2.0	307
3	Alterations of Fas (Apo-1/CD95) gene in non-small cell lung cancer. Oncogene, 1999, 18, 3754-3760.	5.9	249
4	Somatic Mutations of <i>EGFR</i> Gene in Squamous Cell Carcinoma of the Head and Neck. Clinical Cancer Research, 2005, 11, 2879-2882.	7.0	246
5	Inactivating mutations of caspase-8 gene in colorectal carcinomas. Gastroenterology, 2003, 125, 708-715.	1.3	209
6	Somatic Mutations of <i>ERBB2</i> Kinase Domain in Gastric, Colorectal, and Breast Carcinomas. Clinical Cancer Research, 2006, 12, 57-61.	7.0	204
7	Molecular changes from dysplastic nodule to hepatocellular carcinoma through gene expression profiling. Hepatology, 2005, 42, 809-818.	7.3	167
8	Somatic mutations of TRAIL-receptor 1 and TRAIL-receptor 2 genes in non-Hodgkin's lymphoma. Oncogene, 2001, 20, 399-403.	5.9	148
9	A simple, precise and economical microdissection technique for analysis of genomic DNA from archival tissue sections. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 1998, 433, 305-309.	2.8	143
10	Somatic mutations of the trefoil factor family 1 gene in gastric cancer. Gastroenterology, 2000, 119, 691-698.	1.3	141
11	Inactivating mutations of CASP10 gene in non-Hodgkin lymphomas. Blood, 2002, 99, 4094-4099.	1.4	139
12	CASPASE-8 gene is inactivated by somatic mutations in gastric carcinomas. Cancer Research, 2005, 65, 815-21.	0.9	136
13	Alterations of Fas (Apo-1/CD95) Gene in Cutaneous Malignant Melanoma. American Journal of Pathology, 1999, 154, 1785-1791.	3.8	135
14	BRAF and KRAS mutations in stomach cancer. Oncogene, 2003, 22, 6942-6945.	5.9	131
15	Expression of Fas and Fas-related molecules in human hepatocellular carcinoma. Human Pathology, 2001, 32, 250-256.	2.0	107
16	Caspase-8 gene is frequently inactivated by the frameshift somatic mutation 1225_1226delTG in hepatocellular carcinomas. Oncogene, 2005, 24, 141-147.	5.9	107
17	Nuclear localization of ?-catenin is an important prognostic factor in hepatoblastoma. Journal of Pathology, 2001, 193, 483-490.	4.5	106
18	Somatic mutations of CASP3 gene in human cancers. Human Genetics, 2004, 115, 112-5.	3.8	106

#	Article	IF	CITATIONS
19	Mutational analysis of EGFR and K-RAS genes in lung adenocarcinomas. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2005, 446, 483-488.	2.8	102
20	Somatic mutations of the ERBB4kinase domain in human cancers. International Journal of Cancer, 2006, 118, 1426-1429.	5.1	99
21	Non-small cell lung cancers frequently express phosphorylated Akt; an immunohistochemical study. Apmis, 2002, 110, 587-592.	2.0	97
22	Absence of EGFR mutation in the kinase domain in common human cancers besides non-small cell lung cancer. International Journal of Cancer, 2005, 113, 510-511.	5.1	90
23	Inactivating mutations of CASPASE-7 gene in human cancers. Oncogene, 2003, 22, 8048-8052.	5.9	89
24	Somatic Mutations of Fas (Apo-1/CD95) Gene in Cutaneous Squamous Cell Carcinoma Arising from a Burn Scar. Journal of Investigative Dermatology, 2000, 114, 122-126.	0.7	87
25	Alterations of Fas-pathway genes associated with nodal metastasis innon-small cell lung cancer. Oncogene, 2002, 21, 4129-4136.	5.9	75
26	Loss of caspase-2, -6 and -7 expression in gastric cancers. Apmis, 2004, 112, 330-335.	2.0	72
27	Increased expression of FLIP, an inhibitor of Fas-mediated apoptosis, in stomach cancer. Apmis, 2003, 111, 309-314.	2.0	70
28	Mutations of $\hat{l}^2$ -cateninandAXIN Igenes are a late event in human hepatocellular carcinogenesis. Liver International, 2005, 25, 70-76.	3.9	69
29	Genetic alterations of the KLF6 gene in gastric cancer. Oncogene, 2005, 24, 4588-4590.	5.9	69
30	Inactivating mutations of proapoptotic Bad gene in human colon cancers. Carcinogenesis, 2004, 25, 1371-1376.	2.8	68
31	Somatic mutations in the death domain of theFas (Apo-1/CD95) gene in gastric cancer. Journal of Pathology, 2001, 193, 162-168.	4.5	65
32	Hypermethylation of the RUNX3 gene in hepatocellular carcinoma. Experimental and Molecular Medicine, 2005, 37, 276-281.	7.7	61
33	Altered expression of KCNK9 in colorectal cancers. Apmis, 2004, 112, 588-94.	2.0	57
34	Inactivating mutation of the pro-apoptotic geneBID in gastric cancer. Journal of Pathology, 2004, 202, 439-445.	4.5	56
35	Somatic mutations of the ?-TrCP gene in gastric cancer. Apmis, 2007, 115, 127-133.	2.0	53
36	Inactivating mutations of the Siah-1 gene in gastric cancer. Oncogene, 2004, 23, 8591-8596.	5.9	51

3

#	Article	IF	Citations
37	Immunohistochemical analysis of Smac/DIABLO expression in human carcinomas and sarcomas. Apmis, 2003, 111, 382-388.	2.0	48
38	ERBB2 kinase domain mutation in the lung squamous cell carcinoma. Cancer Letters, 2006, 237, 89-94.	7.2	45
39	Immunohistochemical localization of FAPâ€1, an inhibitor of Fasâ€mediated apoptosis, in normal and neoplastic human tissues. Apmis, 1999, 107, 1101-1108.	2.0	44
40	Stomach cancer highly expresses both initiator and effector caspases; an immunohistochemical study. Apmis, 2002, 110, 825-832.	2.0	43
41	Mutational analysis of the ARAF gene in human cancers. Apmis, 2005, 113, 54-7.	2.0	40
42	Mapping of a new target region of allelic loss at 21q22 in primary gastric cancers. Cancer Letters, 2000, 159, 15-21.	7.2	38
43	Decreased expression of Bax-interacting factor-1 (Bif-1) in invasive urinary bladder and gallbladder cancers. Pathology, 2008, 40, 553-557.	0.6	38
44	Genetic and epigenetic alterations of the KLF6 gene in hepatocellular carcinoma. Journal of Gastroenterology and Hepatology (Australia), 2006, 21, 1286-1289.	2.8	35
45	Mutational analysis of proapoptotic caspase-9 gene in common human carcinomas. Apmis, 2006, 114, 292-297.	2.0	35
46	Genetic alterations of the MYH gene in gastric cancer. Oncogene, 2004, 23, 6820-6822.	5.9	34
47	Colorectal tumors frequently express phosphorylated mitogen-activated protein kinase. Apmis, 2004, 112, 233-238.	2.0	32
48	Discriminating the molecular basis of hepatotoxicity using the large-scale characteristic molecular signatures of toxicants by expression profiling analysis. Toxicology, 2008, 249, 176-183.	4.2	32
49	Genetic Alterations of the ATBF1 Gene in Gastric Cancer. Clinical Cancer Research, 2007, 13, 4355-4359.	7.0	29
50	Immunohistochemical analysis of Omi/HtrA2 expression in stomach cancer. Apmis, 2003, 111, 586-590.	2.0	25
51	Application of amplified RNA and evaluation of cRNA targets for spotted-oligonucleotide microarray. Biochemical and Biophysical Research Communications, 2004, 325, 1346-1352.	2.1	25
52	Activation-Induced Cytidine Deaminase Expression in Gastric Cancer. Tumor Biology, 2007, 28, 333-339.	1.8	24
53	Mutational analysis of Noxa gene in human cancers. Apmis, 2003, 111, 599-604.	2.0	19
54	Genetic Alterations and Expression Pattern of CEACAM1 in Colorectal Adenomas and Cancers. Pathology and Oncology Research, 2011, 17, 67-74.	1.9	18

#	Article	IF	CITATIONS
55	<i>ERBB2</i> kinase domain mutation in a gastric cancer metastasis. Apmis, 2005, 113, 683-687.	2.0	17
56	Immunohistochemical analysis of Fas and FLIP in prostate cancers. Apmis, 2009, 117, 28-33.	2.0	17
57	Genetic alterations of the KLF6 gene in colorectal cancers. Apmis, 2006, 114, 458-464.	2.0	16
58	Mutation of FADD gene is rare in human colon and stomach cancers. Apmis, 2004, 112, 595-7.	2.0	8
59	Mutational analysis of the kinase domain of MYLK2 gene in common human cancers. Pathology Research and Practice, 2006, 202, 137-140.	2.3	8
60	Absence of DKC1 exon 3 mutation in common human cancers. Acta Oncolà gica, 2006, 45, 342-343.	1.8	8
61	Mutational analysis of salvador gene in human carcinomas. Apmis, 2003, 111, 595-598.	2.0	7
62	Mutational analysis of MYC in common epithelial cancers and acute leukemias. Apmis, 2006, 114, 436-439.	2.0	7
63	Genetic and epigenetic analysis of the <i>&gt;VHL</i> >gene in gastric cancers. Acta Oncológica, 2008, 47, 1551-1556.	1.8	7
64	Absence of the ERBB2 kinase domain mutation in lung adenocarcinomas in Korean patients. International Journal of Cancer, 2005, 116, 652-653.	5.1	5
65	Mutational analysis of proapoptotic ARTS P-loop domain in common human cancers. Pathology Research and Practice, 2006, 202, 67-70.	2.3	5
66	Mutational analysis of Fas ligand gene in human non-Hodgkin lymphoma. Apmis, 2003, 111, 490-491.	2.0	4
67	Loss-of-function mutations in the Transcription Factor 7 (T cell factor-1) gene in hepatogastrointestinal cancers. Molecular and Cellular Toxicology, 2010, 6, 271-278.	1.7	4
68	Somatic mutation of pro-apoptosis caspase-6 gene is rare in breast and lung carcinomas. Pathology, 2006, 38, 358-359.	0.6	3
69	Kinase domain mutation of ERBB family genes is uncommon in acute leukemias. Leukemia Research, 2006, 30, 241-242.	0.8	3
70	Mutational analysis of P-loop domains of proapoptotic Nod1 and ARTS genes in colon carcinomas. Acta Oncol $\tilde{A}^3$ gica, 2006, 45, 101-102.	1.8	3
71	Absence of E17K mutation in the pleckstrin homology domain of $\langle i \rangle$ AKT1 $\langle  i \rangle$ in gastrointestinal and liver cancers in the Korean population. Apmis, 2008, 116, 530-533.	2.0	2
72	Kinase domain mutation of NTRK3 gene is uncommon in gastric carcinomas. Acta Oncol $\tilde{A}^3$ gica, 2005, 44, 924-925.	1.8	0

#	Article	IF	CITATIONS
73	Absence of the mutation of serine/threonine kinase genes AKT2 and MYLK2 in acute leukemias. European Journal of Haematology, 2006, 77, 175-176.	2.2	o
74	Absence of BH3 Domain Mutations in the Proapoptotic Bcl-2 Gene Family in Non-Hodgkin Lymphomas. Acta Haematologica, 2006, 116, 213-215.	1.4	0